Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn’s disease
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn’s disease
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 51, Issue 11, Pages 1031-1038
Publisher
Wiley
Online
2020-04-24
DOI
10.1111/apt.15719
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study
- (2019) Byong Duk Ye et al. LANCET
- Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
- (2019) Subrata Ghosh et al. DRUG SAFETY
- Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
- (2018) W. J. Sandborn et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience
- (2018) P. Wils et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- ACG Clinical Guideline: Management of Crohn’s Disease in Adults
- (2018) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders
- (2018) Robert P. Hirten et al. Clinical Gastroenterology and Hepatology
- Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series
- (2018) Lydia C T Buer et al. INFLAMMATORY BOWEL DISEASES
- Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
- (2018) Gary R Lichtenstein et al. INFLAMMATORY BOWEL DISEASES
- Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases
- (2018) Joseph Meserve et al. Clinical Gastroenterology and Hepatology
- Serum Concentrations of 7α-hydroxy-4-cholesten-3-one are Associated with Bile Acid Diarrhea in Patients with Crohn’s Disease
- (2018) Robert Battat et al. Clinical Gastroenterology and Hepatology
- The safety of ustekinumab for the treatment of psoriatic arthritis
- (2017) A. López-Ferrer et al. Expert Opinion On Drug Safety
- Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease
- (2017) Magali Lemaitre et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions
- (2016) Laurent Peyrin-Biroulet et al. Clinical Gastroenterology and Hepatology
- The safety of vedolizumab for ulcerative colitis and Crohn's disease
- (2016) Jean-Frédéric Colombel et al. GUT
- A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity
- (2014) R. Khanna et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
- (2012) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort
- (2010) Kelvin T. Thia et al. GASTROENTEROLOGY
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started